Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
03 April 2024 - 11:05PM
Business Wire
- New research demonstrates value of epigenomic analysis and
methylation sequencing with Guardant liquid biopsy portfolio across
continuum of cancer care
- New data show strong performance of Guardant Reveal™ in
detection and quantification of residual disease in early-stage
breast cancer without need for tissue specimen
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced it will present data from nine studies
highlighting advances in methylation-based epigenomic analysis for
precision oncology at the 2024 American Association for Cancer
Research (AACR) Annual Meeting, April 5-10 in San Diego.
Multiple poster sessions will report on the utility of using the
Guardant Infinity™ platform across the continuum of cancer care,
ranging from predictive histologic subtyping of tumors to cardiac
adverse event prediction. Data will also be presented demonstrating
strong performance of Guardant Reveal for minimal residual disease
(MRD) detection in breast cancer, allowing quantification of ctDNA
even in early-stage disease without the need for a tissue
specimen.
“We look forward to sharing new data at AACR, in particular
studies demonstrating the potential for epigenomic analysis using
the Guardant Infinity platform to advance cancer research,” said
Helmy Eltoukhy, Guardant Health chairman and co-CEO. “These
presentations illustrate how epigenomics can unlock the mechanisms
of cancer cell regulation that are invisible to genomic testing,
allowing us to expand patient eligibility for clinical trials and
contributing to targeted therapy development and better-informed
patient care.”
The Guardant Infinity smart liquid biopsy platform used in many
of the studies combines genomic and epigenomic profiling to deliver
multidimensional insights that allow researchers and clinicians to
characterize and quantify cancer—in areas such as tumor
heterogeneity, disease progression and treatment response. The
epigenomic insights enable more personalized treatment strategies
by increasing accuracy in minimal residual disease detection and
monitoring through enhanced ctDNA detection and quantification, and
by identifying new patients or predicting response to therapy
through novel epigenomic biomarkers.
Full List of Guardant Health Presentations
Poster
Title
Product
Sunday, April 7 | 1:30 – 5:00 pm
406/6
Characterization of whole genome
duplication in a genomic cohort of over 14000 cell free DNA
samples
GuardantOMNI®
969/10
Tumor-agnostic ctDNA monitoring in
patients with metastatic HR+/HER2- breast cancer receiving
first-line CDK4/6 inhibitor and endocrine therapy
Guardant Infinity
Monday, April 8 | 9:00 am – 12:30 pm
2390/5
Longitudinal assessment of circulating
tumor DNA in patients with advanced colorectal cancer: A proposed
general statistical framework and visualization tool
GuardantINFORM™
2420/16
Evaluating circulating tumor DNA (ctDNA)
as a prognostic biomarker utilizing a tissue-free epigenomic assay
in early-stage triple negative breast cancer (TNBC)
Guardant Reveal
2490/7
Quantification of tumor fraction and
outcomes association in a real-world non-small cell lung cancer
(NSCLC) cohort using a tissue agnostic epigenomic circulating tumor
DNA (ctDNA) assay
Guardant Infinity
Monday, April 8 | 1:30 – 5:00 pm
3499/21
Non-small cell lung cancer (NSCLC)
histology classification using DNA methylation data captured from
liquid biopsies
Guardant Infinity
3399/1
Prediction of cardiac adverse events (AE)
in trastuzumab treated breast cancer patients (pts) via a
comprehensive genomic and DNA methylation blood based assay
Guardant Infinity
3670/15
Reducing the patient burden for ctDNA
biomarkers: Advancing small volume home-based collection
technologies
Guardant360®
Monday, April 8 | 3:05 – 3:20 pm
Minisymposium - Oral Presentation
3888
TOP1 mutations mediate cross resistance to
ADCs in metastatic breast cancer
GuardantOMNI
The full abstracts for Guardant Health and a list of all
abstracts being presented at the meeting can be found at the AACR
website here.
For more information and updates from the meeting, follow
Guardant Health on LinkedIn, X (Twitter) and Facebook or visit AACR
booth #3545.
About Guardant Health
Guardant Health is a leading precision medicine company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and in
its other reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240403971604/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
317 371 0035
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024